Trigon Investment Banking successfully executed a 64 million PLN Accelerated Bookbuilding transaction for Scope Fluidics S.A., facilitating the sale of borrowed shares to enhance the company's capital for further development in the diagnostics technology sector.
Target Information
Scope Fluidics S.A. is a publicly traded company listed on the Warsaw Stock Exchange, specializing in the development of diagnostics technologies. This strategic initiative was facilitated by Trigon Investment Banking through an Accelerated Bookbuilding (ABB) process, raising a total of 64 million PLN. The transaction involved the sale of existing shares borrowed from the company's founders, contributing to the company's capital enhancement and ongoing project development.
The funds generated from the share sales were allocated to a new issuance of Scope Fluidics shares, aiming to strengthen the company's capital base and support its advancements in diagnostic technology. This innovative approach marks a significant milestone in Scope Fluidics' growth trajectory within an evolving medtech environment.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Poland
The medical technology industry in Poland has witnessed substantial growth, propelled by increased investments in healthcare infrastructure and advancements in research and development. The demand for innovative diagnostic solutions has sur
Similar Deals
Polmed S.A. → Kliniki Neuroradiochirurgii
2024
Trigon
invested in
Scope Fluidics S.A.
in 2025
in a Other deal
Disclosed details
Transaction Size: $16M